Tülin Budak-Alpdoǧan

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 5 papers. Top paper: “Development of a novel Bruton’s tyrosine kinase inhibitor that exerts anti-cancer activities potentiates response of chemotherapeutic agents in multiple myeloma stem cell-like cells”.

Development of a novel Bruton’s tyrosine kinase inhibitor that exerts anti-cancer activities potentiates response of chemotherapeutic agents in multiple myeloma stem cell-like cells

Frontiers in Pharmacology(2022)10.3389/fphar.2022.894535

N/A

0DataRank · unranked

9 citations

Omar S. Al‐Odat, Robert Chitren, J Singh, Sandeep Kumar Srivastava, Krishne Gowda +7 more

Development of a Novel Bruton’s Tyrosine Kinase Inhibitor that exerts Anti-Cancer Activities Potentiates Response of Chemotherapeutic Agents In Multiple Myeloma Stem Cell-Like Cells

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.03.10.483708

N/A

0DataRank · unranked

0 citations

Omar S. Al‐Odat, Robert Chitren, J Singh, Sandeep Kumar Srivastava, Krishne Gowda +6 more

A new efficacious Mcl-1 inhibitor maximizes bortezomib and venetoclax responsiveness in resistant multiple myeloma cells

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.12.06.570435

N/A

0DataRank · unranked

1 citations

Krishne Gowda, Sandeep Kumar Srivastava, Shantu Amin, Subash C. Jonnalagadda, Tülin Budak-Alpdoǧan +2 more

KS18, a Mcl-1 inhibitor, improves the effectiveness of bortezomib and overcomes resistance in refractory multiple myeloma by triggering intrinsic apoptosis

Frontiers in Pharmacology(2024)10.3389/fphar.2024.1436786

N/A

0DataRank · unranked

4 citations

Weam Othman Elbezanti, Krishne Gowda, Sandeep Kumar Srivastava, Shantu Amin, Subash C. Jonnalagadda +3 more

Saga of MCL1 inhibitors in multiple myeloma

Biochemical Pharmacology(2025)10.1016/j.bcp.2025.117532

N/A

0DataRank · unranked

1 citations

S. Telang, Tülin Budak-Alpdoǧan, Subash C. Jonnalagadda, Sandeep Kumar Srivastava, Manoj K. Pandey +1 more